Register for this FREE Solution Provider Webinar: Biomarker Strategies for More Efficient Early-Phase Drug Development in Alzheimer’s Disease

Register for this FREE Solution Provider Webinar
Biomarker Strategies for More Efficient Early-Phase Drug Development in Alzheimer’s Disease
May 21 | 11:00 AM-12:00 PM ET | Online

Brought to you by DIA in cooperation with ICON Plc

The development of validated biomarkers for Alzheimer's disease is essential to improve early diagnosis and accelerate the development of new therapies. It will aid in understanding the mechanism of action of a drug, identifying efficacy or toxicity signals at an early stage of development, and in identifying patients likely to respond to treatment. Biochemical and neuroimaging markers can facilitate diagnosis, predict AD progression from a pre-AD state of mild cognitive impairment (MCI), and monitor efficacies of disease-modifying therapies.

In this FREE webinar, you will learn:
· Drug Development in Alzheimer's Disease – Using Data Analytics to Turn Challenges into
Opportunities
· The Use of Molecular Markers in CSF and Plasma in Alzheimer Disease – The Laboratory Perspective
· Advances in Imaging Biomarkers in AD Drug Development to Enable Accelerated Approval –
Fluorodeoxyglucose PET and Functional MRI
· Recent FDA Draft Guidance on Developing Drugs for Alzheimer’s Disease – Key Considerations
Presenters:
· John Allinson, VP Biomarker Lab Services, ICON Development Solutions, UK
· Niels Prins, MD, PhD, MSc, CEO, Alzheimer Research Center (ARC), Netherlands
· Michael N Liebman, PhD, President/Managing Director, IPQ Analytics, United States
· Klaudius Siegfried, PhD, VP & Global Leader Therapeutic Area CNS (Central Nervous System), ICON
Clinical Research, Germany
Overview | Register Online for FREE!


Sign up for DIA's Global SmartBrief eNews for the latest in drug development innovations worldwide.

Israeli device uses brain stimulation, cognitive training in daily Alzheimer’s treatment

TEL AVIV (Reuters) - Israel-based Neuronix, which has developed a non-invasive medical device to help to treat Alzheimer's disease, expects the system to be approved by the U.S. Food & Drug Administration in late 2014.

The device, which combines electromagnetic stimulation with computer-based cognitive training, is already approved for use in Europe, Israel and several Asian countries such as Singapore.
"You stimulate the brain on a biological level as well as on a cognitive level," Neuronix CEO Eyal Baror told Reuters, saying this double approach created longer-lasting benefits.

The device, which consists of a chair containing an electronic system and software in the back and a coil placed at the head, has been tested on mild to moderate Alzheimer's patients who suffer from dementia but are not totally dependent.

for complete article, Israeli device uses brain stimulation, cognitive training in daily Alzheimer’s treatment